APO Research
Talk to an analyst

APO RESEARCH · REPORT

Neuroprotective Drugs

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Neuroprotective Drugs Industry Growth and Trends Forecast to 2032

22 December 2025103 pages

Choose your research edition.

Industry ResearchNeuroprotective Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Neuroprotective Drugs Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Neuroprotective Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Neuroprotective Drugs Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Neuroprotective Drugs Market Analysis and Forecast 2026-2032196 pages · $4,950 USD

Market perspective

The global Neuroprotective Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Neuroprotective Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Neuroprotective Drugs include Teva Pharmaceutical Industries Ltd, Novartis, Merck KGaA, Biogen, AstraZeneca, NeuroVive Pharmaceutical, Neuren Pharmaceuticals, Genervon Biopharmaceuticals and Ceregene, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Neuroprotective Drugs market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Neuroprotective Drugs market size, estimates, and forecasts are presented in terms of sales volume (tons) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Neuroprotective Drugs market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Neuroprotective Drugs.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global Neuroprotective Drugs market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Neuroprotective Drugs Market by Company

Teva Pharmaceutical Industries Ltd

Novartis

Merck KGaA

Biogen

AstraZeneca

NeuroVive Pharmaceutical

Neuren Pharmaceuticals

Genervon Biopharmaceuticals

Ceregene

Bionure

BHR Pharma

Allon therapeutics

Neuroprotective Drugs Segment by Type

Cholinesterase inhibitors

Anti-inflammatory

Others

Neuroprotective Drugs Segment by Application

Alzheimer's disease

Parkinson's disease

Others

Neuroprotective Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Neuroprotective Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Neuroprotective Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Neuroprotective Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Neuroprotective Drugs manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of Neuroprotective Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of Cholinesterase inhibitors Table 2. Major Company of Anti-inflammatory Table 3. Major Company of Others Table 4. Global Neuroprotective Drugs Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 6. Global Neuroprotective Drugs Sales Market Share in Volume by Type (2021-2026) Table 7. Global Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 8. Global Neuroprotective Drugs Sales Market Share in Value by Type (2021-2026) Table 9. Global Neuroprotective Drugs Price by Type (2021-2026) & (US$/kg) Table 10. Global Neuroprotective Drugs Sales by Type (2027-2032) & (tons) Table 11. Global Neuroprotective Drugs Sales Market Share in Volume by Type (2027-2032) Table 12. Global Neuroprotective Drugs Sales by Type (2027-2032) & (US$ Million) Table 13. Global Neuroprotective Drugs Sales Market Share in Value by Type (2027-2032) Table 14. Global Neuroprotective Drugs Price by Type (2027-2032) & (US$/kg) Table 15. North America Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 16. North America Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 17. Europe Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 18. Europe Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 20. Asia-Pacific Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 22. Latin America Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa Neuroprotective Drugs Sales by Type (2021-2026) & (tons) Table 24. Middle East and Africa Neuroprotective Drugs Sales by Type (2021-2026) & (US$ Million) Table 25. Neuroprotective Drugs Industry Trends Table 26. Neuroprotective Drugs Industry Drivers Table 27. Neuroprotective Drugs Industry Opportunities and Challenges Table 28. Neuroprotective Drugs Industry Restraints Table 29. Global Neuroprotective Drugs Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global Neuroprotective Drugs Revenue Market Share by Company (2021-2026) Table 31. Global Neuroprotective Drugs Sales by Company (2021-2026) & (tons) Table 32. Global Neuroprotective Drugs Sales Share by Company (2021-2026) Table 33. Global Neuroprotective Drugs Market Price by Company (2021-2026) & (US$/kg) Table 34. Global Neuroprotective Drugs Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global Neuroprotective Drugs Major Company Production Sites and Headquarters Table 36. Global Neuroprotective Drugs Company, Product Type & Application Table 37. Global Neuroprotective Drugs Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global Neuroprotective Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global Neuroprotective Drugs Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global Neuroprotective Drugs Sales by Region (2021-2026) & (tons) Table 42. Global Neuroprotective Drugs Sales Market Share in Volume by Region (2021-2026) Table 43. Global Neuroprotective Drugs Sales by Region (2021-2026) & (US$ Million) Table 44. Global Neuroprotective Drugs Sales Market Share in Value by Region (2021-2026) Table 45. Global Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 46. Global Neuroprotective Drugs Sales by Region (2027-2032) & (tons) Table 47. Global Neuroprotective Drugs Sales Market Share in Volume by Region (2027-2032) Table 48. Global Neuroprotective Drugs Sales by Region (2027-2032) & (US$ Million) Table 49. Global Neuroprotective Drugs Sales Market Share in Value by Region (2027-2032) Table 50. Global Neuroprotective Drugs Sales (tons), Value (US$ Million), Price (US$/kg) and Gross Margin (2027-2032) Table 51. Global Neuroprotective Drugs Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 53. Global Neuroprotective Drugs Sales Market Share in Volume by Application (2021-2026) Table 54. Global Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 55. Global Neuroprotective Drugs Sales Market Share in Value by Application (2021-2026) Table 56. Global Neuroprotective Drugs Price by Application (2021-2026) & (US$/kg) Table 57. Global Neuroprotective Drugs Sales by Application (2027-2032) & (tons) Table 58. Global Neuroprotective Drugs Sales Market Share in Volume by Application (2027-2032) Table 59. Global Neuroprotective Drugs Sales by Application (2027-2032) & (US$ Million) Table 60. Global Neuroprotective Drugs Sales Market Share in Value by Application (2027-2032) Table 61. Global Neuroprotective Drugs Price by Application (2027-2032) & (US$/kg) Table 62. North America Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 63. North America Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 64. Europe Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 65. Europe Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 67. Asia-Pacific Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 69. Latin America Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa Neuroprotective Drugs Sales by Application (2021-2026) & (tons) Table 71. Middle East and Africa Neuroprotective Drugs Sales by Application (2021-2026) & (US$ Million) Table 72. Teva Pharmaceutical Industries Ltd Company Information Table 73. Teva Pharmaceutical Industries Ltd Business Overview Table 74. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 75. Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio Table 76. Teva Pharmaceutical Industries Ltd Recent Development Table 77. Novartis Company Information Table 78. Novartis Business Overview Table 79. Novartis Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 80. Novartis Neuroprotective Drugs Product Portfolio Table 81. Novartis Recent Development Table 82. Merck KGaA Company Information Table 83. Merck KGaA Business Overview Table 84. Merck KGaA Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 85. Merck KGaA Neuroprotective Drugs Product Portfolio Table 86. Merck KGaA Recent Development Table 87. Biogen Company Information Table 88. Biogen Business Overview Table 89. Biogen Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 90. Biogen Neuroprotective Drugs Product Portfolio Table 91. Biogen Recent Development Table 92. AstraZeneca Company Information Table 93. AstraZeneca Business Overview Table 94. AstraZeneca Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 95. AstraZeneca Neuroprotective Drugs Product Portfolio Table 96. AstraZeneca Recent Development Table 97. NeuroVive Pharmaceutical Company Information Table 98. NeuroVive Pharmaceutical Business Overview Table 99. NeuroVive Pharmaceutical Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 100. NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio Table 101. NeuroVive Pharmaceutical Recent Development Table 102. Neuren Pharmaceuticals Company Information Table 103. Neuren Pharmaceuticals Business Overview Table 104. Neuren Pharmaceuticals Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 105. Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio Table 106. Neuren Pharmaceuticals Recent Development Table 107. Genervon Biopharmaceuticals Company Information Table 108. Genervon Biopharmaceuticals Business Overview Table 109. Genervon Biopharmaceuticals Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 110. Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio Table 111. Genervon Biopharmaceuticals Recent Development Table 112. Ceregene Company Information Table 113. Ceregene Business Overview Table 114. Ceregene Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 115. Ceregene Neuroprotective Drugs Product Portfolio Table 116. Ceregene Recent Development Table 117. Bionure Company Information Table 118. Bionure Business Overview Table 119. Bionure Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 120. Bionure Neuroprotective Drugs Product Portfolio Table 121. Bionure Recent Development Table 122. BHR Pharma Company Information Table 123. BHR Pharma Business Overview Table 124. BHR Pharma Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 125. BHR Pharma Neuroprotective Drugs Product Portfolio Table 126. BHR Pharma Recent Development Table 127. Allon therapeutics Company Information Table 128. Allon therapeutics Business Overview Table 129. Allon therapeutics Neuroprotective Drugs Sales (tons), Revenue (US$ Million), Price (US$/kg) and Gross Margin (2021-2026) Table 130. Allon therapeutics Neuroprotective Drugs Product Portfolio Table 131. Allon therapeutics Recent Development Table 132. North America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 133. North America Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 134. North America Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 135. North America Neuroprotective Drugs Sales Forecast by Country (2027-2032) & (tons) Table 136. North America Neuroprotective Drugs Sales Market Share Forecast by Country (2027-2032) Table 137. North America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 138. North America Neuroprotective Drugs Market Size by Country (2021-2026) & (US$ Million) Table 139. North America Neuroprotective Drugs Market Share by Country (2021-2026) Table 140. North America Neuroprotective Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 141. North America Neuroprotective Drugs Market Share Forecast by Country (2027-2032) Table 142. Europe Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 143. Europe Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 144. Europe Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 145. Europe Neuroprotective Drugs Sales Forecast by Country (2027-2032) & (tons) Table 146. Europe Neuroprotective Drugs Sales Market Share Forecast by Country (2027-2032) Table 147. Europe Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 148. Europe Neuroprotective Drugs Market Size by Country (2021-2026) & (US$ Million) Table 149. Europe Neuroprotective Drugs Market Share by Country (2021-2026) Table 150. Europe Neuroprotective Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 151. Europe Neuroprotective Drugs Market Share Forecast by Country (2027-2032) Table 152. Asia-Pacific Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 153. Asia-Pacific Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 154. Asia-Pacific Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 155. Asia-Pacific Neuroprotective Drugs Sales Forecast by Country (2027-2032) & (tons) Table 156. Asia-Pacific Neuroprotective Drugs Sales Market Share Forecast by Country (2027-2032) Table 157. Asia-Pacific Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. Asia-Pacific Neuroprotective Drugs Market Size by Country (2021-2026) & (US$ Million) Table 159. Asia-Pacific Neuroprotective Drugs Market Share by Country (2021-2026) Table 160. Asia-Pacific Neuroprotective Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. Asia-Pacific Neuroprotective Drugs Market Share Forecast by Country (2027-2032) Table 162. Latin America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 163. Latin America Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 164. Latin America Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 165. Latin America Neuroprotective Drugs Sales Forecast by Country (2027-2032) & (tons) Table 166. Latin America Neuroprotective Drugs Sales Market Share Forecast by Country (2027-2032) Table 167. Latin America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Latin America Neuroprotective Drugs Market Size by Country (2021-2026) & (US$ Million) Table 169. Latin America Neuroprotective Drugs Market Share by Country (2021-2026) Table 170. Latin America Neuroprotective Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Latin America Neuroprotective Drugs Market Share Forecast by Country (2027-2032) Table 172. Middle East and Africa Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (tons): 2021 VS 2025 VS 2032 Table 173. Middle East and Africa Neuroprotective Drugs Sales by Country (2021-2026) & (tons) Table 174. Middle East and Africa Neuroprotective Drugs Sales Market Share by Country (2021-2026) Table 175. Middle East and Africa Neuroprotective Drugs Sales Forecast by Country (2027-2032) & (tons) Table 176. Middle East and Africa Neuroprotective Drugs Sales Market Share Forecast by Country (2027-2032) Table 177. Middle East and Africa Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Middle East and Africa Neuroprotective Drugs Market Size by Country (2021-2026) & (US$ Million) Table 179. Middle East and Africa Neuroprotective Drugs Market Share by Country (2021-2026) Table 180. Middle East and Africa Neuroprotective Drugs Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Middle East and Africa Neuroprotective Drugs Market Share Forecast by Country (2027-2032) Table 182. Key Raw Materials Table 183. Raw Materials Key Suppliers Table 184. Neuroprotective Drugs Distributors List Table 185. Neuroprotective Drugs Customers List Table 186. Research Programs/Design for This Report Table 187. Authors List of This Report Table 188. Secondary Sources Table 189. Primary Sources List of Figures Figure 1. Neuroprotective Drugs Image Figure 2. Global Neuroprotective Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Neuroprotective Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Neuroprotective Drugs Sales (2021-2032) & (tons) Figure 5. Cholinesterase inhibitors Image Figure 6. Global Cholinesterase inhibitors Sales YoY Growth (2021-2032) & (tons) Figure 7. Anti-inflammatory Image Figure 8. Global Anti-inflammatory Sales YoY Growth (2021-2032) & (tons) Figure 9. Others Image Figure 10. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 11. Global Neuroprotective Drugs Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global Neuroprotective Drugs Market Share by Type 2025 VS 2032 Figure 13. North America Neuroprotective Drugs Sales Market Share in Volume by Type in 2025 Figure 14. North America Neuroprotective Drugs Sales Market Share in Value by Type in 2025 Figure 15. Europe Neuroprotective Drugs Sales Market Share in Volume by Type in 2025 Figure 16. Europe Neuroprotective Drugs Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific Neuroprotective Drugs Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific Neuroprotective Drugs Sales Market Share in Value by Type in 2025 Figure 19. Latin America Neuroprotective Drugs Sales Market Share in Volume by Type in 2025 Figure 20. Latin America Neuroprotective Drugs Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa Neuroprotective Drugs Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa Neuroprotective Drugs Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 Neuroprotective Drugs Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Alzheimer's disease Image Figure 26. Global Alzheimer's disease Sales YoY Growth (2021-2032) & (tons) Figure 27. Parkinson's disease Image Figure 28. Global Parkinson's disease Sales YoY Growth (2021-2032) & (tons) Figure 29. Others Image Figure 30. Global Others Sales YoY Growth (2021-2032) & (tons) Figure 31. Global Neuroprotective Drugs Market Size Overview by Application (2021-2032) & (US$ Million) Figure 32. Global Neuroprotective Drugs Market Share by Application 2025 VS 2032 Figure 33. North America Neuroprotective Drugs Sales Market Share in Volume by Application in 2025 Figure 34. North America Neuroprotective Drugs Sales Market Share in Value by Application in 2025 Figure 35. Europe Neuroprotective Drugs Sales Market Share in Volume by Application in 2025 Figure 36. Europe Neuroprotective Drugs Sales Market Share in Value by Application in 2025 Figure 37. Asia-Pacific Neuroprotective Drugs Sales Market Share in Volume by Application in 2025 Figure 38. Asia-Pacific Neuroprotective Drugs Sales Market Share in Value by Application in 2025 Figure 39. Latin America Neuroprotective Drugs Sales Market Share in Volume by Application in 2025 Figure 40. Latin America Neuroprotective Drugs Sales Market Share in Value by Application in 2025 Figure 41. Middle East and Africa Neuroprotective Drugs Sales Market Share in Volume by Application in 2025 Figure 42. Middle East and Africa Neuroprotective Drugs Sales Market Share in Value by Application in 2025 Figure 43. North America Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 44. North America Neuroprotective Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 45. North America Neuroprotective Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. North America Neuroprotective Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 48. Europe Neuroprotective Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 49. Europe Neuroprotective Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 50. Europe Neuroprotective Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 52. Asia-Pacific Neuroprotective Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 53. Asia-Pacific Neuroprotective Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 54. Asia-Pacific Neuroprotective Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 56. Latin America Neuroprotective Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 57. Latin America Neuroprotective Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Latin America Neuroprotective Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa Neuroprotective Drugs Sales by Country: 2021 VS 2025 VS 2032 (tons) Figure 60. Middle East and Africa Neuroprotective Drugs Sales Share by Country: 2021 VS 2025 VS 2032 Figure 61. Middle East and Africa Neuroprotective Drugs Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 62. Middle East and Africa Neuroprotective Drugs Market Share by Country: 2021 VS 2025 VS 2032 Figure 63. Neuroprotective Drugs Value Chain Figure 64. Key Raw Materials Price Figure 65. Manufacturing Cost Structure Figure 66. Neuroprotective Drugs Production Mode & Process Figure 67. Direct Comparison with Distribution Share Figure 68. Distributors Profiles Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Cholinesterase inhibitors
  • Anti-inflammatory
  • Others
Applications
  • Alzheimer's disease
  • Parkinson's disease
  • Others
Companies covered
  • Teva Pharmaceutical Industries Ltd
  • Novartis
  • Merck KGaA
  • Biogen
  • AstraZeneca
  • NeuroVive Pharmaceutical
  • Neuren Pharmaceuticals
  • Genervon Biopharmaceuticals
  • Ceregene
  • Bionure
  • BHR Pharma
  • Allon therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Neuroprotective Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global Neuroprotective Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.3 Neuroprotective Drugs Market by Type
  6. 1.3.1 Cholinesterase inhibitors
  7. 1.3.2 Anti-inflammatory
  8. 1.3.3 Others
  9. 1.4 Global Neuroprotective Drugs Market Size by Type
  10. 1.4.1 Global Neuroprotective Drugs Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global Neuroprotective Drugs Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global Neuroprotective Drugs Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America Neuroprotective Drugs Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe Neuroprotective Drugs Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific Neuroprotective Drugs Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America Neuroprotective Drugs Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa Neuroprotective Drugs Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 Neuroprotective Drugs Industry Trends
  2. 2.2 Neuroprotective Drugs Industry Drivers
  3. 2.3 Neuroprotective Drugs Industry Opportunities and Challenges
  4. 2.4 Neuroprotective Drugs Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by Neuroprotective Drugs Revenue (2021-2026)
  2. 3.2 Global Top Players by Neuroprotective Drugs Sales (2021-2026)
  3. 3.3 Global Top Players by Neuroprotective Drugs Price (2021-2026)
  4. 3.4 Global Neuroprotective Drugs Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Neuroprotective Drugs Major Company Production Sites & Headquarters
  6. 3.6 Global Neuroprotective Drugs Company, Product Type & Application
  7. 3.7 Global Neuroprotective Drugs Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Neuroprotective Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Neuroprotective Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Neuroprotective Drugs Tier 1, Tier 2, and Tier 3
4 Neuroprotective Drugs Regional Status and Outlook
  1. 4.1 Global Neuroprotective Drugs Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global Neuroprotective Drugs Historic Market Size by Region
  3. 4.2.1 Global Neuroprotective Drugs Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global Neuroprotective Drugs Sales in Value by Region (2021-2026)
  5. 4.2.3 Global Neuroprotective Drugs Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global Neuroprotective Drugs Forecasted Market Size by Region
  7. 4.3.1 Global Neuroprotective Drugs Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global Neuroprotective Drugs Sales in Value by Region (2027-2032)
  9. 4.3.3 Global Neuroprotective Drugs Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 Neuroprotective Drugs by Application
  1. 5.1 Neuroprotective Drugs Market by Application
  2. 5.1.1 Alzheimer's disease
  3. 5.1.2 Parkinson's disease
  4. 5.1.3 Others
  5. 5.2 Global Neuroprotective Drugs Market Size by Application
  6. 5.2.1 Global Neuroprotective Drugs Market Size Overview by Application (2021-2032)
  7. 5.2.2 Global Neuroprotective Drugs Historic Market Size Review by Application (2021-2026)
  8. 5.2.3 Global Neuroprotective Drugs Forecasted Market Size by Application (2027-2032)
  9. 5.3 Key Regions Market Size by Application
  10. 5.3.1 North America Neuroprotective Drugs Sales Breakdown by Application (2021-2026)
  11. 5.3.2 Europe Neuroprotective Drugs Sales Breakdown by Application (2021-2026)
  12. 5.3.3 Asia-Pacific Neuroprotective Drugs Sales Breakdown by Application (2021-2026)
  13. 5.3.4 South America Neuroprotective Drugs Sales Breakdown by Application (2021-2026)
  14. 5.3.5 Middle East and Africa Neuroprotective Drugs Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Teva Pharmaceutical Industries Ltd
  2. 6.1.1 Teva Pharmaceutical Industries Ltd Company Information
  3. 6.1.2 Teva Pharmaceutical Industries Ltd Business Overview
  4. 6.1.3 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Teva Pharmaceutical Industries Ltd Neuroprotective Drugs Product Portfolio
  6. 6.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Neuroprotective Drugs Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Merck KGaA
  14. 6.3.1 Merck KGaA Company Information
  15. 6.3.2 Merck KGaA Business Overview
  16. 6.3.3 Merck KGaA Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Merck KGaA Neuroprotective Drugs Product Portfolio
  18. 6.3.5 Merck KGaA Recent Developments
  19. 6.4 Biogen
  20. 6.4.1 Biogen Company Information
  21. 6.4.2 Biogen Business Overview
  22. 6.4.3 Biogen Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Biogen Neuroprotective Drugs Product Portfolio
  24. 6.4.5 Biogen Recent Developments
  25. 6.5 AstraZeneca
  26. 6.5.1 AstraZeneca Company Information
  27. 6.5.2 AstraZeneca Business Overview
  28. 6.5.3 AstraZeneca Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 AstraZeneca Neuroprotective Drugs Product Portfolio
  30. 6.5.5 AstraZeneca Recent Developments
  31. 6.6 NeuroVive Pharmaceutical
  32. 6.6.1 NeuroVive Pharmaceutical Company Information
  33. 6.6.2 NeuroVive Pharmaceutical Business Overview
  34. 6.6.3 NeuroVive Pharmaceutical Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 NeuroVive Pharmaceutical Neuroprotective Drugs Product Portfolio
  36. 6.6.5 NeuroVive Pharmaceutical Recent Developments
  37. 6.7 Neuren Pharmaceuticals
  38. 6.7.1 Neuren Pharmaceuticals Company Information
  39. 6.7.2 Neuren Pharmaceuticals Business Overview
  40. 6.7.3 Neuren Pharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Neuren Pharmaceuticals Neuroprotective Drugs Product Portfolio
  42. 6.7.5 Neuren Pharmaceuticals Recent Developments
  43. 6.8 Genervon Biopharmaceuticals
  44. 6.8.1 Genervon Biopharmaceuticals Company Information
  45. 6.8.2 Genervon Biopharmaceuticals Business Overview
  46. 6.8.3 Genervon Biopharmaceuticals Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Genervon Biopharmaceuticals Neuroprotective Drugs Product Portfolio
  48. 6.8.5 Genervon Biopharmaceuticals Recent Developments
  49. 6.9 Ceregene
  50. 6.9.1 Ceregene Company Information
  51. 6.9.2 Ceregene Business Overview
  52. 6.9.3 Ceregene Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Ceregene Neuroprotective Drugs Product Portfolio
  54. 6.9.5 Ceregene Recent Developments
  55. 6.10 Bionure
  56. 6.10.1 Bionure Company Information
  57. 6.10.2 Bionure Business Overview
  58. 6.10.3 Bionure Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Bionure Neuroprotective Drugs Product Portfolio
  60. 6.10.5 Bionure Recent Developments
  61. 6.11 BHR Pharma
  62. 6.11.1 BHR Pharma Company Information
  63. 6.11.2 BHR Pharma Business Overview
  64. 6.11.3 BHR Pharma Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 BHR Pharma Neuroprotective Drugs Product Portfolio
  66. 6.11.5 BHR Pharma Recent Developments
  67. 6.12 Allon therapeutics
  68. 6.12.1 Allon therapeutics Company Information
  69. 6.12.2 Allon therapeutics Business Overview
  70. 6.12.3 Allon therapeutics Neuroprotective Drugs Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Allon therapeutics Neuroprotective Drugs Product Portfolio
  72. 6.12.5 Allon therapeutics Recent Developments
7 North America by Country
  1. 7.1 North America Neuroprotective Drugs Sales by Country
  2. 7.1.1 North America Neuroprotective Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America Neuroprotective Drugs Sales by Country (2021-2026)
  4. 7.1.3 North America Neuroprotective Drugs Sales Forecast by Country (2027-2032)
  5. 7.2 North America Neuroprotective Drugs Market Size by Country
  6. 7.2.1 North America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America Neuroprotective Drugs Market Size by Country (2021-2026)
  8. 7.2.3 North America Neuroprotective Drugs Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe Neuroprotective Drugs Sales by Country
  2. 8.1.1 Europe Neuroprotective Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe Neuroprotective Drugs Sales by Country (2021-2026)
  4. 8.1.3 Europe Neuroprotective Drugs Sales Forecast by Country (2027-2032)
  5. 8.2 Europe Neuroprotective Drugs Market Size by Country
  6. 8.2.1 Europe Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe Neuroprotective Drugs Market Size by Country (2021-2026)
  8. 8.2.3 Europe Neuroprotective Drugs Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific Neuroprotective Drugs Sales by Country
  2. 9.1.1 Asia-Pacific Neuroprotective Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific Neuroprotective Drugs Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific Neuroprotective Drugs Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific Neuroprotective Drugs Market Size by Country
  6. 9.2.1 Asia-Pacific Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific Neuroprotective Drugs Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific Neuroprotective Drugs Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America Neuroprotective Drugs Sales by Country
  2. 10.1.1 South America Neuroprotective Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America Neuroprotective Drugs Sales by Country (2021-2026)
  4. 10.1.3 South America Neuroprotective Drugs Sales Forecast by Country (2027-2032)
  5. 10.2 South America Neuroprotective Drugs Market Size by Country
  6. 10.2.1 South America Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America Neuroprotective Drugs Market Size by Country (2021-2026)
  8. 10.2.3 South America Neuroprotective Drugs Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa Neuroprotective Drugs Sales by Country
  2. 11.1.1 Middle East and Africa Neuroprotective Drugs Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa Neuroprotective Drugs Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa Neuroprotective Drugs Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa Neuroprotective Drugs Market Size by Country
  6. 11.2.1 Middle East and Africa Neuroprotective Drugs Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa Neuroprotective Drugs Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa Neuroprotective Drugs Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 Neuroprotective Drugs Value Chain Analysis
  2. 12.1.1 Neuroprotective Drugs Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 Neuroprotective Drugs Production Mode & Process
  7. 12.2 Neuroprotective Drugs Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 Neuroprotective Drugs Distributors
  10. 12.2.3 Neuroprotective Drugs Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst